Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable. A literature search was done, and a total of 49 studies published from 1949 to 2021 were included. All published studies were case reports. A total number of 59 patients were included: 50 men and nine women. Multiple types of bladder cancer were described, 72.8% were urothelial/transitional cell carcinoma of different grades and stages (n=43). Other reported cancers were adenocarcinoma of the bladder (n=4), poorly differentiated carcinoma (n=5), bladder sarcoma (n=1), sarcomatoid carcinoma (n=1), renal cell carcinoma (n=1), myeloid sarcoma (n=1), and grade III papillary carcinoma (n=2). The most common site for cutaneous lesions was the abdomen, followed by the chest. Further randomized cohort studies assessing the sites and patterns of metastasis should be done to help physicians in their clinical work.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669487 | PMC |
http://dx.doi.org/10.7759/cureus.74439 | DOI Listing |
World J Urol
January 2025
Department of Urology, Saint Marianna University School of Medicine, Kawasaki, Japan.
Purposes: This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra.
Methods: Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra.
Cancer Discov
January 2025
Salk Institute for Biological Studies, La Jolla, CA, United States.
Identities of functional pSer/Thr.Pro protein substrates of the PIN1 prolyl isomerase and its effects on downstream signaling in bladder carcinogenesis remain largely unknown. Phenotypically, we found that PIN1 positively regulated bladder cancer cell proliferation, cell motility and urothelium clearance capacity in vitro and controlled tumor growth and potential metastasis in vivo.
View Article and Find Full Text PDFAlzheimers Dement
January 2025
The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.
Observational studies on the cancer-dementia relationship have yielded controversial results. This study systematically reviews the evidence to clarify this association. We searched Embase, Global Health, Ovid Medline, and APA PsycInfo.
View Article and Find Full Text PDFBJU Int
January 2025
EADV Task Force on Tattoos and Body Art, Lugano, Switzerland.
Tech Innov Patient Support Radiat Oncol
March 2025
Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Tokushima 770-8503, Japan.
Purpose: This study aims to compare treatment plans created using RapidPlan and PlanIQ for twelve patients with prostate cancer, focusing on dose uniformity, dose reduction to organs at risk (OARs), plan complexity, and dose verification accuracy. The goal is to identify the tool that demonstrates superior performance in achieving uniform target dose distribution and reducing OAR dose, while ensuring accurate dose verification.
Methods: Dose uniformity in the planning target volume, excluding the rectum, and dose reduction in the OARs (the rectum and bladder) were assessed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!